Key result
Targeted nanotechnology-based therapies directed at white adipose tissue and its vasculature offer a promising alternative strategy to combat obesity with high tolerability and reduced side effects.
Why the study?
Current anti-obesity drugs are limited by non-specificity and unsustainable weight loss effects, necessitating novel targeted approaches such as nanotechnology-based therapies.
Does targeted nanotherapy reduce obesity and prevent its comorbidities in preclinical models compared to conventional therapies?
Does targeted nanotherapy reduce obesity and prevent its comorbidities in preclinical models compared to conventional therapies?
Nanotechnology-based targeted therapies directed at white adipose tissue vasculature offer a promising, highly specific alternative to conventional anti-obesity drugs with potentially fewer systemic side effects.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for targeted nanotherapy in obesity; leaves open clinical translation and efficacy trials.
Obesity through its association with type 2 diabetes (T2D), cancer and cardiovascular diseases (CVDs), poses a serious health threat, as these diseases contribute to high mortality rates. Pharmacotherapy alone or in combination with either lifestyle modification or surgery, is reliable in maintaining a healthy body weight, and preventing progression to obesity-induced diseases. However, the anti-obesity drugs are limited by non-specificity and unsustainable weight loss effects. As such, novel and improved approaches for treatment of obesity are urgently needed. Nanotechnology-based therapies are investigated as an alternative strategy that can treat obesity and be able to overcome the drawbacks associated with conventional therapies. The review presents three nanotechnology-based anti-obesity strategies that target the white adipose tissues (WATs) and its vasculature for the reversal of obesity. These include inhibition of angiogenesis in the WATs, transformation of WATs to brown adipose tissues (BATs), and photothermal lipolysis of WATs. Compared to conventional therapy, the targeted-nanosystems have high tolerability, reduced side effects, and enhanced efficacy. These effects are reproducible using various nanocarriers (liposomes, polymeric and gold nanoparticles), thus providing a proof of concept that targeted nanotherapy can be a feasible strategy that can combat obesity and prevent its comorbidities.
No takes yet. Share an insight, caveat, or question.
Sibuyi et al. (2019) conducted a review in Obesity. Nanotechnology-based targeted therapies vs. Conventional pharmacotherapy was evaluated. Targeted nanotechnology-based therapies directed at white adipose tissue and its vasculature offer a promising alternative strategy to combat obesity with high tolerability and reduced side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: